Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2018

Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody

20181107 SITC Joint BioInvent Transgene EN

Published 7 November 2018
Categorized as 2018, Invir.IO, Press release

NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform

Press Release NEC- Transgene EN

Published 30 October 2018
Categorized as 2018, Myvac, Press release

€26.6 million in cash and cash equivalents as of September 30, 2018

20181025 PR Q3-2018 EN

Published 25 October 2018
Categorized as 2018, Press release

First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors

20181017 PR TG6002 US

Published 17 October 2018
Categorized as 2018, Press release, TG6002

Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018

20181010 AASLD Abstract Poster EN

Published 10 October 2018
Categorized as 2018, Press release, TG1050

Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference

20181001 SITC Poster VEN

Published 2 October 2018
Categorized as 2018, Invir.IO, Myvac, Press release

Transgene unveils myvac™, an individualized immunotherapy against solid tumors

20180924 MyVac EN

Published 24 September 2018
Categorized as 2018, Myvac, Press release

Transgene Presents 2018 Half-Year Results and Business Update

20180919 H1 2018 RESULTS EN

Published 19 September 2018
Categorized as 2018, Press release

Transgene Announces Upcoming Investor Meetings

20180903 PR financial agenda H2 18

Published 3 September 2018
Categorized as 2018, Press release

Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares

180820 – TG Tasly Closing EN

Published 20 August 2018
Categorized as 2018, Press release, TG1050, TG6002

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu